Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies ...

The grant was approved by the Compensation Committee on March 16, 2025, pursuant to a delegation by the Board of Directors and was issued as an equity grant pursuant to Nasdaq Listing Rule 5635 (c) (4 ...

The approved inducement grant comes as Etsy targets a stickier app experience as part of a strategy to reverse an ongoing ...

The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan”) as an inducement material to this ...

The grant was offered as material inducement to Zamansky’s employment as Amwell’s chief product and technology officer. The RSUs become vested as follows, subject to Zamansky’s continued ...

Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.

Such grant was made under The Honest Company, Inc. 2023 Inducement Plan, which was approved and adopted on March 14, 2023, by the Company’s Compensation Committee of the Board of Directors.

The stock option granted on November 5, 2024 has a ten-year term and an exercise price of $3.59 per share, which is equal to ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious ...

The Honest Company (NASDAQ: HNST), a personal care company dedicated to creating cleanly-formulated and sustainably-designed products, today announced that ...